Aspirin News and Research RSS Feed - Aspirin News and Research

Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients. [More]
WSU collaborates with Botanisol to study and develop new anti-inflammatory drug

WSU collaborates with Botanisol to study and develop new anti-inflammatory drug

Work on a new anti-inflammatory drug developed from the medicinal/spice plant turmeric recently received funding from a $225,000 grant from the National Institutes of Health National Center for Complementary and Integrative Health. [More]
Experts reveal link between excess body weight and colorectal cancer risk

Experts reveal link between excess body weight and colorectal cancer risk

Experts speaking at the 23rd United European Gastroenterology Week (UEG Week 2015) in Barcelona, Spain today revealed compelling evidence of the link between excess body weight and risk of colorectal cancer (CRC). John Mathers, Professor of Human Nutrition from the Institute of Cellular Medicine at Newcastle University in the UK presented data showing an overall increase of 18% in relative risk of CRC per 5 unit increase in BMI. [More]
Major UK trial to examine role of aspirin in cancer recurrence

Major UK trial to examine role of aspirin in cancer recurrence

The world's largest ever clinical trial looking at whether taking aspirin every day stops some of the most common cancers coming back, launches across the UK today (Thursday). [More]
Study reveals poor levels of use, availability and affordability of cardiovascular disease medicines worldwide

Study reveals poor levels of use, availability and affordability of cardiovascular disease medicines worldwide

New research published in The Lancet shows that the use of vital life-saving generic (and supposedly inexpensive) medicines for prevention in people with existing heart disease is poor worldwide. In low-income and middle-income countries these medicines are not widely available and, when available, can often be unaffordable. In rich countries, although such medicines are both available and affordable, 35% to 50% of patients who have heart disease or a previous stroke still do not receive them. [More]
Radical shift required in use of heart medicine worldwide

Radical shift required in use of heart medicine worldwide

Many people in the world who need essential heart medicine do not get it, even in rich countries, says new research published today in the medical journal The Lancet. [More]
Research finding offers hope for more powerful aspirin-like drugs

Research finding offers hope for more powerful aspirin-like drugs

Researchers have found that salicylic acid targets the activities of HMGB1, an inflammatory protein associated with a wide variety of diseases, offering hope that more powerful aspirin-like drugs may be developed. [More]
U.S 2nd Annual Obesity Summit: 35 major U.S. health societies see how they can treat obesity

U.S 2nd Annual Obesity Summit: 35 major U.S. health societies see how they can treat obesity

Representatives from 35 major health and medical organizations including, the American Diabetes Association (ADA), American Medical Association (AMA), American Heart Association (AHA), American Academy of Orthopaedic Surgeons (AAOS), and American Society of Clinical Oncology (ASCO) convened for a second annual summit in Chicago to identify opportunities for collaboration in treating obesity. “The National Obesity Summit on the Provision of Care for the Obese Patient” was hosted by the American Society for Metabolic and Bariatric Surgery (ASMBS). [More]
Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan plc, a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation. [More]
Study may lead to new insights on use of aspirin in GI cancer

Study may lead to new insights on use of aspirin in GI cancer

Aspirin improves survival in patients with tumours situated throughout the gastrointestinal (GI) tract, results from a large study in The Netherlands show. This is the first time that survival data from patients with tumours in different GI locations have been analysed at the same time; previously, only one type of cancer, usually colorectal, was studied. [More]
BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

Researchers from Brigham and Women's Hospital and Dana-Farber Cancer Institute have received a $10 million Breakthrough Award from the Department of Defense's Office of the Congressionally Directed Medical Research Program to test whether aspirin helps women with breast cancer avoid recurrence and live longer. [More]
Researchers show how a cell surface protein can mobilize immune cells to attack malignant tumors

Researchers show how a cell surface protein can mobilize immune cells to attack malignant tumors

Revealing a biological combat strategy worthy of a five-star general, researchers from Houston Methodist Hospital, University of Chicago and Cornell University have shown how a cell surface receptor--a specialized protein which communicates signals between a cell and the outside world--can mobilize immune cells to attack, rather than protect, malignant tumors. [More]
Regular physical trauma may put professional football players at increased risk for hypertension

Regular physical trauma may put professional football players at increased risk for hypertension

The regular physical trauma that appears to put professional football players at risk for degenerative brain disease may also increase their risk for hypertension and cardiovascular disease, researchers say. [More]
Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States. [More]
Aspirin may help boost effectiveness of cancer treatment

Aspirin may help boost effectiveness of cancer treatment

Giving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell today (Thursday). [More]
Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications has increased over the past ten years in ischaemic heart disease but levels are still suboptimal, according to the first results of the Chronic Ischaemic Cardiovascular Disease (CICD) Pilot Registry presented today at ESC Congress 2015 and published in European Heart Journal. [More]
Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF). [More]
Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada. [More]
DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Fatal bleeding is rare with extended dual antiplatelet therapy, according to a secondary analysis of the DAPT Study presented for the first time today at ESC Congress. Bleeding-related mortality accounted for a minority of deaths in patients treated with dual antiplatelet therapy beyond one year. [More]
Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today. [More]
Advertisement
Advertisement